Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes.

Nicolas Musi, Laurie J. Goodyear

Research output: Contribution to journalReview articlepeer-review

70 Scopus citations

Abstract

The AMP-activated protein kinase (AMPK) is an energy-sensing enzyme that is activated in response to conditions of cellular stress such as muscle contraction and hypoxia. In skeletal muscle, activation of AMPK leads to increased glucose uptake, enhanced insulin sensitivity and oxidation of fatty acids. In the liver, AMPK activation causes an increase in fatty acid oxidation and inhibition of glucose production. These effects on glucose and fat metabolism make AMPK an important pharmacological target for the treatment of type 2 diabetes. Studies done in animal models of type 2 diabetes have shown that pharmacological activation of AMPK with the compound 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) decreases blood glucose and insulin concentrations. While strong efforts are underway in order to identify novel AMPK-activating compounds, the safety of chronic pharmacological activation of AMPK remains to be determined.

Original languageEnglish (US)
Pages (from-to)119-127
Number of pages9
JournalCurrent drug targets. Immune, endocrine and metabolic disorders
Volume2
Issue number2
DOIs
StatePublished - Jul 2002
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes.'. Together they form a unique fingerprint.

Cite this